# Profound **Source:** https://geo.sig.ai/brands/profound **Vertical:** healthcare **Subcategory:** AI medical imaging **Tier:** Leader **Website:** tryprofound.com **Last Updated:** 2026-04-14 ## Summary FDA-cleared AI breast cancer detection suite by iCAD (acquired by RadNet 2025). ProFound AI reads 40M+ mammograms globally with 23% improved detection rate. ## Company Overview Profound AI is the medical imaging AI brand developed by iCAD, a pioneer in cancer detection technology. iCAD's ProFound AI platform applies deep learning to mammography analysis, providing radiologists with AI-powered decision support that identifies suspicious lesions, calculates cancer risk scores, and prioritizes reading worklists based on AI-assessed urgency. The system is designed to function as a second reader — augmenting rather than replacing radiologist judgment — by flagging findings that warrant closer attention and reducing the cognitive load on radiologists reviewing high volumes of routine screening mammograms.\n\nProFound AI has achieved FDA clearance as a medical device for breast cancer detection, enabling its use in clinical radiology workflows across US health systems. The platform processes mammograms in real time, integrating with existing PACS and radiology information systems so it can be deployed without disrupting established workflow. Its clinical validation studies have demonstrated a 23% improvement in cancer detection rate compared to unassisted reads, while simultaneously reducing false positives — a combination that is clinically meaningful and commercially compelling for radiology practices seeking to improve outcomes without adding radiologist time.\n\nProFound AI reads over 40 million mammograms globally, making it one of the most widely deployed FDA-cleared AI systems in radiology. iCAD was acquired by RadNet in 2025, integrating ProFound into one of the largest radiology network operators in the United States. This acquisition significantly expands ProFound's deployment footprint, as RadNet operates hundreds of imaging centers across the US and has the scale to make AI-assisted mammography a standard-of-care offering. The combination of FDA clearance, proven clinical performance, massive global deployment, and integration into a major radiology network positions ProFound AI as a market-defining product in cancer detection AI. ## Frequently Asked Questions ### What is ProFound AI? ProFound AI is an FDA-cleared deep learning solution for breast cancer detection in 2D and 3D mammography, offering cancer detection, density assessment, and short-term risk evaluation. ### How effective is ProFound AI? Radiologists using ProFound AI see a 23% relative increase in cancer detection without increasing recall rates, and Version 4.0 offers 50% improved detection in dense breasts. ### Who owns ProFound AI? ProFound AI was developed by iCAD, Inc. which was acquired by RadNet, Inc. in July 2025. It is available in over 50 countries. ### What is Profound Medical? Profound Medical is a medical technology company specializing in TULSA-PRO — a transurethral ultrasound ablation system for treating prostate cancer that uses MRI-guided focused ultrasound to ablate prostate tissue while preserving urinary and sexual function. ### What is TULSA-PRO? TULSA-PRO (Transurethral Ultrasound Ablation) is Profound's FDA-approved treatment system that uses real-time MRI thermometry to guide precise, personalized thermal ablation of prostate cancer, offering patients an alternative to surgery and radiation with reduced side effects. ### How does TULSA-PRO differ from radiation therapy? TULSA-PRO treats prostate cancer in a single outpatient session using focused ultrasound heat guided by MRI, achieving precise tissue destruction without the treatment course, side effects, or secondary cancer risks associated with radiation therapy. ### How much has Profound Medical raised? Profound Medical trades on NASDAQ and TSX under ticker PROF, having raised capital through public markets to commercialize TULSA-PRO across US and European urology centers. ### What is the market for Profound's technology? Prostate cancer is the most common cancer in men with over 250,000 new cases annually in the US. TULSA-PRO targets the segment seeking focal or whole-gland treatment with better functional outcome preservation than traditional prostatectomy or radiation. ### What is Profound's technology and what clinical problem does it address? Profound Medical develops TULSA-PRO, an MRI-guided transurethral ultrasound ablation system for treating prostate cancer and BPH (benign prostatic hyperplasia). The technology enables precise, real-time MRI-guided thermal ablation of prostate tissue without surgery, potentially offering superior quality-of-life outcomes versus conventional treatments. ### How does TULSA-PRO work technically? TULSA-PRO uses a transurethral ultrasound device placed within the urethra while the patient lies in an MRI scanner. The system delivers ultrasound energy to heat and ablate prostate tissue while the MRI provides real-time temperature mapping guidance, enabling the physician to precisely control the ablation boundary to conform to the tumor or BPH tissue while protecting surrounding structures. ### What advantages does TULSA-PRO offer over traditional prostate cancer treatment? TULSA-PRO offers outpatient treatment with real-time imaging guidance, the ability to target specific prostate zones while potentially sparing nerves and sphincter function, and the option for retreatment if needed. Compared to radical prostatectomy or radiation, whole-gland or focal TULSA-PRO treatment may offer comparable cancer control with fewer impacts on continence and sexual function. ### What is Profound's regulatory and commercial status? Profound Medical (Nasdaq: PROF) has received FDA clearance and CE mark for TULSA-PRO for prostate tissue ablation. The company is commercially launching in the US, Canada, and Europe at hospitals with MRI-interventional capabilities, targeting urologists and radiation oncologists treating localized prostate cancer and BPH patients. ### Who are Profound's competitors in prostate treatment technology? Profound competes with established prostate cancer treatments including radical prostatectomy (robotic surgery with Intuitive Surgical's da Vinci), radiation (Varian, Elekta), focal laser ablation, and cryotherapy. It also competes with Sonablate HIFU (high-intensity focused ultrasound) systems from SonaCare for focal prostate ablation. The competitive positioning centers on MRI guidance precision advantage. ## Tags healthtech, b2b --- *Data from geo.sig.ai Brand Intelligence Database. Updated 2026-04-14.*